This Article Full Text Full Text (PDF) All Versions of this Article: 2006-0327OCv1 37/2/222    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singleton, P. A. Articles by Garcia, J. G. N. Search for Related Content PubMed PubMed Citation Articles by Singleton, P. A. Articles by Garcia, J. G. N.

Attenuation of Vascular Permeability by Methylnaltrexone

Role of mOP-R and S1P3 Transactivation

Department of Medicine, and Department of Anesthesia and Critical Care, University of Chicago, Chicago, Illinois

Correspondence and requests for reprints should be addressed to Joe G. N. Garcia, M.D., Department of Medicine, University of Chicago Pritzker School of Medicine, 5841 S. Maryland Avenue, W604, Chicago, IL 60637. E-mail: jgarcia{at}medicine.bsd.uchicago.edu

Endothelial cell (EC) barrier dysfunction (i.e., increased vascular permeability) is observed in inflammatory states, tumor angiogenesis, atherosclerosis, and both sepsis and acute lung injury. Therefore, agents that preserve vascular integrity have important clinical therapeutic implications. We examined the effects of methylnaltrexone (MNTX), a mu opioid receptor (mOP-R) antagonist, on human pulmonary EC barrier disruption produced by edemagenic agents including morphine, the endogenous mOP-R agonist DAMGO, thrombin, and LPS. Pretreatment of EC with MNTX (0.1 µM, 1 h) or the uncharged mOP-R antagonist naloxone attenuated morphine- and DAMGO-induced barrier disruption in vitro. However, MNTX, but not naloxone, pretreatment of EC inhibited thrombin- and LPS-induced barrier disruption, indicating potential mOP-R–independent effects of MNTX. In addition, intravenously delivered MNTX attenuated LPS-induced vascular hyperpermeability in the murine lung. We next examined the mechanistic basis for this MNTX barrier protection and observed that silencing of mOP-R attenuated the morphine- and DAMGO-induced EC barrier disruption, but not the permeability response to either thrombin or LPS. Because activation of the sphingosine 1-phosphate receptor, S1P₃, is key to a number of barrier-disruptive responses, we examined the role of this receptor in the permeability response to mOP-R ligation. Morphine, DAMGO, thrombin, and LPS induced RhoA/ROCK-mediated threonine phosphorylation of S1P₃, which was blocked by MNTX, suggesting S1P₃ transactivation. In addition, silencing of S1P₃ receptor expression (siRNA) abolished the permeability response to each edemagenic agonist. These results indicate that MNTX provides barrier protection against edemagenic agonists via inhibition of S1P₃ receptor activation and represents a potentially useful therapeutic agent for syndromes of increased vascular permeability.

Key Words: methylnaltrexone • mu opioid receptor • S1P3 receptor • EC barrier regulation • vascular permeability

This article has been cited by other articles:

				S. Uhlig and E. Gulbins Sphingolipids in the Lungs Am. J. Respir. Crit. Care Med., December 1, 2008; 178(11): 1100 - 1114. [Abstract] [Full Text] [PDF]

				P. A. Singleton, J. G.N. Garcia, and J. Moss Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis Mol. Cancer Ther., June 1, 2008; 7(6): 1669 - 1679. [Abstract] [Full Text] [PDF]